ReviewDeutsches Arzteblatt international2016
The Indications, Applications, and Risks of Proton Pump Inhibitors.
Review in Deutsches Arzteblatt international, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it, 89 citations in OpenAlex.
- A Systematic Review of Gastric Acid-Reducing Agent-Mediated Drug-Drug Interactions with Orally Administered Medications.Clinical pharmacokinetics · 2020Pooled it
- Efficacy and safety of hangeshashinto for treatment of GERD refractory to proton pump inhibitors : Usual dose proton pump inhibitors plus hangeshashinto versus double-dose proton pump inhibitors: randomized, multicenter open label exploratory study.Journal of gastroenterology · 2019Trial
- Synergistic Potential of Repurposing non-β-lactam Compounds as Class A serine β-lactamases Inhibitor: Insights from MolecularDocking, Molecular Dynamics Simulations and Antimicrobial Potentiation.Scientific reports · 2026Article
- Proton-pump inhibitor exposure and prevalence of colorectal adenoma: a retrospective analysis from the Sakkopi study.BMJ open gastroenterology · 2026Article
- Beyond acid suppression: the multifaceted role of proton pump inhibitors inFrontiers in microbiology · 2026Review
- The 10 top prescribed medicines in Germany from 1985 to 2022: pharmacological analysis.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Article
- Peptic Ulcer Disease.The Korean journal of helicobacter and upper gastrointestinal research · 2025Review
- Nonsteroidal Anti-Inflammatory Drug-Induced Peptic Ulcer Disease.The Korean journal of helicobacter and upper gastrointestinal research · 2025Review
- Comprehensive insights on treatment modalities with conventional and herbal drugs for the treatment of duodenal ulcers.Naunyn-Schmiedeberg's archives of pharmacology · 2024Review
- Impact of Helicobacter pylori Eradication on Surgical Treatment of Peptic Ulcer Disease: Systematic Review.Cureus · 2024Review
- Comparing AGS Beers 2019, STOPP version 2, and EU(7)-PIM list in Portuguese older adults in primary health care.European journal of clinical pharmacology · 2024Article
- Gut Microbiota-Gut Metabolites andMetabolites · 2024Review
- Safety of Proton Pump Inhibitors in Pediatric Population: A Systematic Review.Global pediatric health · 2024Review
- Review
- Patients' perspectives on a patient-oriented electronic decision support tool to reduce overuse of proton pump inhibitors (arriba-PPI): a qualitative study in primary care.BMC primary care · 2023Article
- Review
- Article
- Proton Pump Inhibitors and the Risk of Early Aseptic Loosening in Hip and Knee Arthroplasty.Geriatric orthopaedic surgery & rehabilitation · 2022Article
- Proton pump inhibitors and the risk of Alzheimer's disease and non-Alzheimer's dementias.Scientific reports · 2020Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProton pump inhibitors (PPI) are the most effective drugs for inhibiting gastric acid secretion. They have been in clinical use for more than 25 years, In 2014, 3.475 billion daily defined doses (DDD) of PPI were prescribed in Germany. This high number alone calls for a critical analysis of the spectrum of indications for PPI and their potential adverse effects.
methodsThis review is based on pertinent publications retrieved by a selective search in the PubMed and Cochrane Library databases, with particular emphasis on randomized, prospective multicenter trials, cohort studies, case-control studies, and meta-analyses.
resultsThe inhibition of gastric acid secretion with PPI is successfully used for the treatment of gastroesophageal reflux disease and of gastric and duodenal ulcers, for the secondary prevention of gastroduodenal lesions that have arisen under treatment with nonsteroidal anti-inflammatory drugs and acetylsalicylic acid, and for the prevention of recurrent hemorrhage from ulcers after successful endoscopic hemostasis. PPI are given along with practically all antibiotic regimens for the eradication of Helicobacter pylori infection. The number of prescriptions for PPI has risen linearly over the past 25 years. As there has been no broadening of indications, one may well ask whether the current, extensive use of PPI is justified. There is evidence that patients taking PPI are at greater risk for fractures. Moreover, the vitamin B12 level should be checked occasionally in all patients taking PPI.
conclusionPPI are among the more effective drugs for the treatment of diseases associated with gastric acid. In view of their cost and potential adverse effects, they should only be prescribed for scientifically validated indications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.